Blake Borgeson - 07 Jul 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 07 Jul 2026
Net transaction value: -$158,500
SEC form: 4
Accepted by SEC: 09 Jul 2026, 18:04:18 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/Jonathan Golightly, attorney-in-fact

Key filing fact

Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 09 Jul 2026.

Key facts

This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jul 2026, 18:04.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: -$158,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001856094 Primary reporting owner

Borgeson Blake

Relationship: Director
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/Jonathan Golightly, attorney-in-fact
Signature date: 09 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Sale

Transaction value: $158,500
Shares: -40,000
Change %: -0.64%
Price: $3.96
Shares after: 6,218,287
Date: 07 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.